Status:
COMPLETED
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies
Lead Sponsor:
Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Conditions:
Invasive Fungal Infections
Eligibility:
All Genders
Brief Summary
The primary objective of this study is to evaluate invasive fungal infections (IFI) according to clinicians' opinion vs the opinion of an independent board of experts. The primary output of this study...
Detailed Description
Primary objective The primary objective of this study is to evaluate IFI according to clinicians' opinion vs the opinion of an independent board of experts. The independent panel, confirming or not th...
Eligibility Criteria
Inclusion
- All patients with hematologic malignancies at any stage of the disease (acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia, high and low grade non Hodgkin lymphoma, chronic myeloprolipherative disorders, Hodgkin lymphoma);
- Only inpatients will be eligible;
- Patient that start IV antifungal treatment (irrespective of previous prophylaxis);
- Informed consent signed.
Exclusion
- Patients with previous or undergoing allogeneic or autologous transplant will be excluded from the study, due to different clinical profiles and risk factors;
- Patients treated, after prophylaxis with oral antifungals
- Patients treated in outpatient clinic or Day hospital
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
513 Patients enrolled
Trial Details
Trial ID
NCT04024995
Start Date
September 1 2019
End Date
December 31 2021
Last Update
October 26 2022
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Universitaria S. Orsola Malpighi
Bologna, Italy
2
ASST-Spedali Civili
Brescia, Italy
3
AOUC Carreggi
Florence, Italy
4
AOU Policlinico Federico II
Napoli, Italy